Influence of switching to travoprost on intraocular pressure of uncontrolled chronic open-angle glaucoma patients compliant to previously-used topical medication

Current Medical Research and Opinion

Volumn 21, Issue 12, 2005, Pages 1943-1948

  Holló, Gábor ^a   Vargha, Péter ^a   Kóthy, Péter ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Compliance; Intraocular pressure; Travoprost

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; LATANOPROST; TRAVOPROST;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONJUNCTIVAL HYPEREMIA; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG RESPONSE; DRUG SUBSTITUTION; DRY EYE; DYSPNEA; EYE COLOR; EYE DISEASE; EYE INFLAMMATION; EYELASH; FEMALE; HEADACHE; HEART PALPITATION; HUMAN; INTRAOCULAR FOREIGN BODY; INTRAOCULAR HYPOTENSION; INTRAOCULAR PRESSURE; IRIS DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; OCULAR PRURITUS; OPEN ANGLE GLAUCOMA; PATIENT COMPLIANCE; PATIENT MONITORING; PATIENT PARTICIPATION; PHASE 4 CLINICAL TRIAL; SAMPLE SIZE; SKIN ALLERGY; UNIVERSITY HOSPITAL; VISUAL IMPAIRMENT;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; CLOPROSTENOL; FEMALE; GLAUCOMA, OPEN-ANGLE; HUMANS; INTRAOCULAR PRESSURE; MALE; MIDDLE AGED; PATIENT COMPLIANCE;

EID: 29144497065     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X74916     Document Type: Article

References (12)

1. Feldman RL, Sullivan EK, Ratliff M, et al. Comparison of travoprost 0.0015% and 0.004% with timolol in patients with elevated intraocular pressure. Ophthalmology 2001;109:998-1008
2. Goldberg I, Cunha-Vaz J, Jakobsen J-E, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma and ocular hypertension. J Glaucoma 2001;10:414-22
3. Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
4. Orengo-Nania S, Landry T, Von Tress M, et al. Evaluation of travoprost as adjunctive therapy in patients with uncontrolled intraocular pressure while using timolol 0.5%. Am J Ophthalmol 2001;132:860-8
5. Parrish RK, Palmberg P, Sheu W-P; for the XLT Study Group. A comparison of latanoprost, bimatoprost and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
6. Kaback M, Geanon J, Katz G, et al. Ocular hypotensive efficacy of travoprost in patients unsuccessfully treated with latanoprost. Curr Med Res Opin 2004;20:1341-5
7. Przydryga JT, Engloff C and the Swiss START Study Group. Intraocular pressure lowering efficacy of travoprost. Eur J Ophthalmol 2004;14:416-22
8. Martinez-de-la-Casa JM, Castillo A, Garcia-Feijoo J, et al. Concomitant administration of travoprost and brinzolamide versus fixed latanoprost/timolol combined therapy: three-month comparison of the efficacy and safety. Curr Med Res Opin 2004;20:1333-9
9. Dubiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:84-91
10. Hellberg MR, SAllee VL, McLaughlin MA, et al. Preclinical efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist. J Ocular Pharmacol Ther 2001;17:421-32
11. Olthoff CMG, Schouten JSAG, de Borne BW, Webers CAB. Noncompliance with ocular hypotensive treatment in patients with glaucoma or ocular hypertension. Ophthalmology 2005;112:953-61
12. Steinert RF, Thomas JV, Boger WP. Long-term drift and continued efficacy after multiyear timolol therapy. Arch Ophthalmol 1981;99:100-3